Home » China Approves Imports of J&J’s Tremfya
China Approves Imports of J&J’s Tremfya
China’s National Medical Products Administration has cleared Johnson and Johnson’s Tremfya (guselkumab) for importation.
The agency approved the drug for treatment of moderate-to-severe plaque psoriasis in adults who are suitable for systemic therapy.
J&J is positioning Tremfya as an alternative to Novartis’ Cosentyx (secukinumab), one of the top selling psoriasis treatments.
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May